Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China
Patients receiving methadone maintenance treatment (MMT) elicited poor response and rapid anti-HBs loss after standard hepatitis B vaccination. An optimal hepatitis B vaccination was urgent. A randomized, parallel-controlled trial was conducted in patients receiving MMT from 2019 to 2020, and patien...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2447108 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841525462024585216 |
|---|---|
| author | Xinyuan Mo Zhaoyue Men Linying Gao Yizhuo Gao Tian Yao Yuan Liu Yuan Yuan Tongchuan Xue Fuzhen Wang Suping Wang Keke Wang Xiaofeng Liang Yongliang Feng |
| author_facet | Xinyuan Mo Zhaoyue Men Linying Gao Yizhuo Gao Tian Yao Yuan Liu Yuan Yuan Tongchuan Xue Fuzhen Wang Suping Wang Keke Wang Xiaofeng Liang Yongliang Feng |
| author_sort | Xinyuan Mo |
| collection | DOAJ |
| description | Patients receiving methadone maintenance treatment (MMT) elicited poor response and rapid anti-HBs loss after standard hepatitis B vaccination. An optimal hepatitis B vaccination was urgent. A randomized, parallel-controlled trial was conducted in patients receiving MMT from 2019 to 2020, and patients were randomized to receive 3 or 4 doses of 20 or 60 µg of hepatitis B vaccine. Follow-up was extended to 2021, for assessment of 1-year persistence of immunogenicity at month 18. A total of 145 participants completed the 1-year follow-up. From month 7 to 18, the response rates of the IM60 × 4 group, IM20 × 4 group, and IM20 × 3 group decreased from 95.52% (64/67) to 84.09% (37/44), 94.67% (71/75) to 78.72% (37/47), and 89.19% (66/74) to 68.52% (37/54), respectively. No significant differences were observed in the persistence of vaccine-induced responses among the three groups (p = .204). All three hepatitis B vaccine regimens demonstrated comparable declines in anti-HBs levels, with a rapid decrease observed within 1-year of follow-up.Clinical trial registration ClinicalTrials.gov (NCT03962816).https://clinicaltrials.gov/ct2/show/NCT03962816 |
| format | Article |
| id | doaj-art-754ee66b82084d10ab14359757d0c2d0 |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-754ee66b82084d10ab14359757d0c2d02025-01-17T12:52:10ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2024.2447108Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in ChinaXinyuan Mo0Zhaoyue Men1Linying Gao2Yizhuo Gao3Tian Yao4Yuan Liu5Yuan Yuan6Tongchuan Xue7Fuzhen Wang8Suping Wang9Keke Wang10Xiaofeng Liang11Yongliang Feng12School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, ChinaSchool of Public Health, Shanxi Medical University, Taiyuan, Shanxi, ChinaSchool of Public Health, Shanxi Medical University, Taiyuan, Shanxi, ChinaSchool of Public Health, Shanxi Medical University, Taiyuan, Shanxi, ChinaCenter of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, Shanxi, ChinaMethadone Maintenance Treatment Clinic, Compulsory Isolation Drug Rehabilitation Center, Taiyuan, Shanxi, ChinaMethadone Maintenance Treatment Clinic, 109 hospital, Taiyuan, Shanxi, ChinaXinghualing District Methadone Maintenance Treatment Clinic, Taiyuan, Shanxi, ChinaChinese Center for Disease Control and Prevention, Beijing, ChinaSchool of Public Health, Shanxi Medical University, Taiyuan, Shanxi, ChinaFirst Hospital/First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, ChinaInstitute of Vaccine Industry, Institute of Disease Control and Prevention, Jinan University, Guangzhou, Guangdong, ChinaSchool of Public Health, Shanxi Medical University, Taiyuan, Shanxi, ChinaPatients receiving methadone maintenance treatment (MMT) elicited poor response and rapid anti-HBs loss after standard hepatitis B vaccination. An optimal hepatitis B vaccination was urgent. A randomized, parallel-controlled trial was conducted in patients receiving MMT from 2019 to 2020, and patients were randomized to receive 3 or 4 doses of 20 or 60 µg of hepatitis B vaccine. Follow-up was extended to 2021, for assessment of 1-year persistence of immunogenicity at month 18. A total of 145 participants completed the 1-year follow-up. From month 7 to 18, the response rates of the IM60 × 4 group, IM20 × 4 group, and IM20 × 3 group decreased from 95.52% (64/67) to 84.09% (37/44), 94.67% (71/75) to 78.72% (37/47), and 89.19% (66/74) to 68.52% (37/54), respectively. No significant differences were observed in the persistence of vaccine-induced responses among the three groups (p = .204). All three hepatitis B vaccine regimens demonstrated comparable declines in anti-HBs levels, with a rapid decrease observed within 1-year of follow-up.Clinical trial registration ClinicalTrials.gov (NCT03962816).https://clinicaltrials.gov/ct2/show/NCT03962816https://www.tandfonline.com/doi/10.1080/21645515.2024.2447108Persistence of immunogenicityhepatitis B vaccinationmethadone maintenance treatmentparallel-controlled trialrandomized controlled trial |
| spellingShingle | Xinyuan Mo Zhaoyue Men Linying Gao Yizhuo Gao Tian Yao Yuan Liu Yuan Yuan Tongchuan Xue Fuzhen Wang Suping Wang Keke Wang Xiaofeng Liang Yongliang Feng Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China Human Vaccines & Immunotherapeutics Persistence of immunogenicity hepatitis B vaccination methadone maintenance treatment parallel-controlled trial randomized controlled trial |
| title | Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China |
| title_full | Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China |
| title_fullStr | Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China |
| title_full_unstemmed | Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China |
| title_short | Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China |
| title_sort | immunogenicity persistence after four intramuscular triple dose or standard dose hepatitis b vaccine in patients receiving methadone maintenance treatment a 1 year follow up study in china |
| topic | Persistence of immunogenicity hepatitis B vaccination methadone maintenance treatment parallel-controlled trial randomized controlled trial |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2447108 |
| work_keys_str_mv | AT xinyuanmo immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT zhaoyuemen immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT linyinggao immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT yizhuogao immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT tianyao immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT yuanliu immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT yuanyuan immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT tongchuanxue immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT fuzhenwang immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT supingwang immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT kekewang immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT xiaofengliang immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina AT yongliangfeng immunogenicitypersistenceafterfourintramusculartripledoseorstandarddosehepatitisbvaccineinpatientsreceivingmethadonemaintenancetreatmenta1yearfollowupstudyinchina |